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ABSTRACT
Members of the apolipoprotein BmRNA-editing enzyme-catalytic polypeptide-like-3 (APOBEC3) innate cellular cytidine
deaminase family, particularly APOBEC3F and APOBEC3G, can cause extensive and lethal G-to-Amutations in HIV-1 plus-
strand DNA (termed hypermutation). It is unclear if APOBEC3-induced mutations in vivo are always lethal or can occur at sub-
lethal levels that increase HIV-1 diversification and viral adaptation to the host. The viral accessory protein Vif counteracts
APOBEC3 activity by binding to APOBEC3 and promoting proteasome degradation; however, the efficiency of this interaction
varies, since a range of hypermutation frequencies are observed in HIV-1 patient DNA. Therefore, we examined “footprints” of
APOBEC3G and APOBEC3F activity in longitudinal HIV-1 RNA pol sequences from approximately 3,000 chronically infected
patients by determining whether G-to-Amutations occurred in motifs that were favored or disfavored by these deaminases. G-
to-Amutations were more frequent in APOBEC3G-disfavored than in APOBEC3G-favored contexts. In contrast, mutations in
APOBEC3F-disfavored contexts were relatively rare, whereas mutations in contexts favoring APOBEC3F (and possibly other
deaminases) occurred 16%more often than average G-to-Amutations. These results were supported by analyses of>500 HIV-1
env sequences from acute/early infection.
IMPORTANCE
Collectively, our results suggest that APOBEC3G-inducedmutagenesis is lethal to HIV-1, whereas mutagenesis caused by
APOBEC3F and/or other deaminases may result in sublethal mutations that might facilitate viral diversification. Therefore, Vif-
specific cytotoxic T lymphocyte (CTL) responses and drugs that manipulate the interplay between Vif and APOBEC3may have
beneficial or detrimental clinical effects depending on how they affect the binding of Vif to various members of the APOBEC3
family.
Human immunodeficiency virus type 1 (HIV-1) continuouslyadapts to selection pressures in infected individuals. Because
of its small genome, highmutation rate, large population size, and
rapid turnover rate, nearly all HIV-1 single-mutation variants are
produced in most untreated hosts each day, and any variant with
the slightest survival advantage rapidly prevails (1). The high mu-
tation rate of HIV-1 has been linked to the high error rate of
HIV-1 reverse transcriptase (RT) and RNA polymerase II (RNA
Pol II) (2) and to innate cellular cytidine deaminases, such as
apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-
like 3 (APOBEC3) (3).
Several members of the APOBEC3 family (APOBEC3A to
APOBEC3H) have antiviral effects; however, APOBEC3F and
APOBEC3G exert the strongest levels of antiviral activity and are
the primary restriction factors inhibitingHIV-1 replication in hu-
man primary CD4 T cells, the key HIV-1 target cells (4). During
reverse transcription, APOBEC3F and APOBEC3G induce cyt-
idine-to-uridine (C-to-U) deamination of single-stranded mi-
nus-strand HIV-1 DNA, which generates guanosine-to-adeno-
sine (G-to-A) mutations in plus-strand DNA (3, 5–11). These
G-to-A mutations occur in APOBEC3F- and APOBEC3G-fa-
vored di-, tri- and tetranucleotide contexts (the GGnn-to-AGnn
andGAnn-to-AAnn contexts, respectively [12]) (themutated nu-
cleotide residue is underlined). The remaining APOBEC3 pro-
teins favor the same dinucleotide context as APOBEC3F. Because
G-to-A transitions far exceed all other mutations, the mutated
provirus is referred to as “hypermutated.”
This intrinsic cellular defense mechanism is thwarted by the
HIV-1-encoded protein Vif, which mediates APOBEC3 degrada-
tion. Vif simultaneously binds toAPOBEC3 and to a cellular ubiq-
uitin ligase (cullin5 [Cul5]-elongin [Elo]B/C-Rbx)) through dis-
tinct amino acids motifs (13, 14). This binding induces the
polyubiquitination of both APOBEC3 and Vif, which are then
Received 20 May 2014 Accepted 21 August 2014
Published ahead of print 27 August 2014
Editor: S. R. Ross
Address correspondence to Astrid K. N. Iversen, astrid.iversen@ndcn.ox.ac.uk.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/JVI.01460-14.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.01460-14
12882 jvi.asm.org Journal of Virology p. 12882–12894 November 2014 Volume 88 Number 21
 o
n
 O
ctober 28, 2014 by KU Leuven University Library
http://jvi.asm.org/
D
ow
nloaded from
 
targeted for proteasomal degradation (3, 15–20). This process de-
pletes the pool of cytosolic APOBEC3 that is available for incor-
poration into assembling viral particles and reduces the risk of
HIV-1 hypermutation in the next infected cell.
However, the efficiency of the Vif-APOBEC3 interaction
clearly varies among hosts, because a range of hypermutation fre-
quencies has been observed inHIV-1DNA from infected patients.
Whereas the lowest observed levels of APOBEC3G-induced hy-
permutation in vitro are highly likely to introduce multiple lethal
stop codonswithinHIV-1 (21), it is unclear whether some or all of
the APOBEC3 proteins induce mutations at sublethal levels that
increase viral diversification in vivo. Such increased diversification
may facilitate viral adaptation to selective pressures in the host and
thereby enhance HIV-1 propagation.
To determine if APOBEC3-induced mutagenesis can facilitate
HIV-1 evolution, we focused on APOBEC3F and APOBEC3G.
We examined longitudinal HIV-1 sequences from3,000 chron-
ically infected patients to detect polymorphisms that were indic-
ative of APOBEC3F or APOBEC3G activity (i.e., APOBEC3F or
APOBEC3G “footprints”) by determining whether G-to-Amuta-
tions occurred in motifs that were favored or disfavored by the
deaminases. Because the remaining APOBEC3 proteins favor the
APOBEC3F-favored dinucleotide context, the APOBEC3F foot-
prints could be generated by APOBEC3F and/or other deami-
nases. We hypothesized that deleterious mutations, even if nonle-
thal, would be quickly eliminated from the population and that
the footprints would indicate remaining deaminase-induced mu-
tations that were selectively neutral or possibly advantageous to
the viruses.
MATERIALS AND METHODS
HIV-1 RNA sequences from patients without hypermutated viruses
during chronic infection.Weobtained a curated set of 5,614 longitudinal
pairs of partial pol sequences (average length  1,084 bp) from 3,190
patients who were previously analyzed by Deforche et al. (22). The se-
quences were generated using population sequencing and originated with
the Stanford Drug Resistance Database in Palo Alto, CA (23), the Univer-
sity Hospitals in Leuven, Belgium, and Hospital Egas Monis in Lisbon,
Portugal. Briefly, HIV-1 was amplified from plasma samples and se-
quenced using various clinically validated genotypic in-house (24) or
commercial tests (e.g., Bayer Health Diagnostics’ HIV-1 TrueGene and
Celera Diagnostics/Abbott Laboratories’ ViroSeq) (Fig. 1A). These assays
produce a consensus sequence representative of the circulating and ac-
tively replicatingHIV population in the patient, and these sequences were
used to decide the patients’ antiretroviral treatments (24, 25).
The data were curated by creating phylogenetic trees using the soft-
ware program PAUP (26). Codons at positions that were associated with
drug resistance mutations in protease (positions 30, 46, 48, 50, 54, 56, 82,
84, 88, and 90) and reverse transcriptase (41, 44, 65, 67, 70, 74, 75, 77, 100,
103, 106, 108, 115, 116, 151, 181, 184, 188, 190, 210, 215, and 219) (27)
were excluded to avoid the confounding effects of convergent evolution
on the tree reconstructions (28). Sequence pairs from the same patient
that did not cluster together in the tree (suggesting either contamination
or HIV-1 superinfection) were excluded (a total of 450 sequence pairs).
Each of the remaining 5,614 sequence pairs contained two sequences (Fig.
1B). Because 2 to 4 sequences were available from each patient, we ob-
tained 1 to 3 pairs per patient. However, 1 or 2 pairs weremost commonly
observed. All of the sequence pairs represented the total number of avail-
able sequences per patient. The genetic distance was estimated using
PAUP, and the sequences were subtyped using the subtyping tool in the
HIV database (www.hiv.lanl.gov). If dual HIV-1 infections were present
in all samples from a given patient, it would have added unbiased noise to
the population sequencing results, limiting the resolution of our analyses.
However, the quality of all sequence reads was carefully evaluated at the
time patient treatment was decided, and signs of dual infections were not
observed either during proofreading of the sequences or during the phy-
logenetic clustering analysis. No CD4 counts or viral load data were avail-
able.
Maximum-likelihood-based nucleotidemisincorporation rate esti-
mator. A modification of the method developed by Deforche et al. (22)
was used to estimate the misincorporation rates of the observed substitu-
tions in the serially sampled sequences. The misincorporation rates of
individual mutations will depend on their mutation rates, the other mu-
tations with which they cooccur, and the effects of natural selection on the
protein sequence. Because we are interested in the first two factors, we
corrected for changes to the protein sequence by considering the relative
rates of changes whose effects on the amino acid sequence were equiva-
lent.
Briefly, nucleotide substitutions were considered equivalent when
they had the same effect at the amino acid level (i.e., they either changed
the motif to encode the same amino acid or were silent mutations),
and the observed nucleotide substitution was considered against the al-
ternative equivalent substitution alone. The observed nonsynonymous
substitutions, which could have been achieved by alternative equivalent
nucleotide substitutions (e.g., a Phe-to-Leu mutation may be caused by a
TTC-to-CTC (T-to-C)mutation rather than the alternative TTC-to-TTA
(C-to-A) or TTC-to-TTG (C-to-G) mutations, and synonymous substi-
tutions were used to generate themaximum-likelihood estimation (MLE)
of the misincorporation rates (Fig. 1C). In our analyses, we implemented
two novel models. To assess the influence of the two downstream nucle-
otides on observed G-to-A misincorporation rates, the first model in-
cluded parameters that estimated the GGn-to-AGn (APOBEC3G-type)
misincorporation rates, and the second model included parameters that
estimated the GAn-to-AAn (APOBEC3F-type) misincorporation rates.
Both models integrated the following parameters: (i) 11 parameters that
corresponded to the relative rates of misincorporation other than those
for the A-to-C change, which was used as a reference; (ii) a parameter that
corrected for a bias toward G-to-A mutations that remove CpG (i.e.,
CG-to-CA); (iii) a parameter that corrected for a bias toward other mu-
tations that remove CpG; and (iv) a parameter that corrected for a bias
against mutations that create CpG. Therefore, all of the mutation rates
should reflect the context-dependent bias in the generation of the muta-
tions (e.g., mediated by the APOBEC3 proteins or RT and/or RNAPol II),
or unknown selection factors not associated with the amino acid se-
quences or selection against CpGmotifs. This analysis is not based on the
frequency of observed mutations but on estimating a preference for a
certain observed mutation over possible alternative mutations, which
have the same influence on the amino acid sequence. Consequently, the
analysis looks at relative rates ofmutation between trinucleotide contexts,
rather than simply plotting the proportion that are mutated. The set of
cross-sectional acute and early HIV-1 sequences (29) was analyzed based
on APOBECF and APOBEC3G dinucleotide preferences.
Ethics statement. The research was conducted according to the Dec-
laration of Helsinki. Informed consent was obtained from all of the pa-
tients according to the regulations of each country regarding experimen-
tation using human tissue. The protocol and this consent procedure were
approved by the Ethical Committee UZ Leuven (reference ML-8627, ap-
proval B322201316521 S52637).
The sequence accession numbers from GenBank and the Stanford
Drug Resistance Database can be found in Table S1 in the supplemental
material, whereas sequence identifiers (IDs) from the EuResist database
can be made available to researchers after submission of a study protocol
to EUresist (http://www.euresist.org) and study approval by the local eth-
ical committee. The EUresist sequence IDs cannot bemade availablewith-
out study approval because the IDs are linked to patient treatment and the
patients’ informed consents are time limited.
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RESULTS
Analyses of longitudinal HIV-1 pol sequences from patients
without hypermutated viruses during chronic infection. To in-
vestigate if sublethal APOBEC3-induced mutagenesis occurs in
natural HIV-1 infection, we analyzed the curated set of longitudi-
nal pairs of HIV-1 pol RNA sequences from 3,190 chronically
infected patients for APOBEC3F and APOBEC3G footprints. The
pairs comprised 2 to 4 sequences per patient. For each patient, we
first compared the sequences from the first and second time points
(equal to one pair), followed by the sequences from the second
and third time points (equal to a second pair) and those from the
third and fourth time points (equal to a third pair) when appro-
priate. The sequences were sampled over 1 to 3 years. The median
time from baseline to follow-up was 469 days (25 to 75% quartile
range, 231 to 894). The sequences were all derived from HIV-1
RNA isolated from plasma, and none were hypermutated. The
mean genetic distance was 0.017 nucleotide substitutions per site.
Approximately 90% of the sequences belonged to subtype B, 4%
to subtype G, and the remainder to other subtypes, circulating
recombinant forms (CRF), or unique recombinant forms (URF).
Dual infections were not observed in the cohort.
A previous study used this data set and APOBEC3G- and
APOBEC3F-dinucleotide contexts to examine the relative impor-
tances of RT andAPOBEC3 for theG-to-Amisincorporation rates
in HIV-1 (22). Although that study confirmed the previously de-
scribed bias toward G-to-A mutations in HIV-1 (30–32),
APOBEC3G or APOBEC3F footprints could not be reliably de-
tected.We previously determined the tri- and tetranucleotide tar-
get preferences for APOBEC3F and APOBEC3G (12), which en-
abled us to study the influence of the downstream nucleotide on
3,190 HIV+ patients
PCR and population sequencing 
8446 pol sequences 
(1,084 bp each)  
CACCGCATCGAAATTAACTTCCAAAGTTAAGCTTGG 
A.
B.
CACCGCATCGAAATTAACTTCCAAAGTTAAGCTTGA
Baseline sequence, patient X, time = 0
CACCGCATCAAAATTAACTTCCAAAGTTAAGCTTGA 
Sequence 2 from patient X, time = +6 months
CACCGCATCAAAATTAACTTCCAAAGTTAAGCTTAA 
Sequence 3 from patient X, time = +12 months
Sequence pair 1 Sequence pair 2
C.
Sequence validation 
removal of drug resistance mutations
and phylogenetic curating 
Equivalent substitutions
Patient X, baseline sequence   --- GTC GAT TTC AGA ---
Val    Asp   Phe   Arg
 
Patient X, follow-up sequence  --- GTT GAT CTC AGA ---
Val    Asp   Leu   Arg
GTC GTT
Val to Val
Observed
Alternative GTC GTA
GTC GTG
TTC CTC
Phe to Leu
Observed
Alternative TTC TTA
TTC TTG
Equivalent substitutions
Non-synonymous mutation
Synonymous mutation P(C T ) = 
r( )
r( ) Ar( ) Gr( )+ +GTC GTT
C T
C T C C 
P( TTC CTC
T C
T C ) = 
r( )
T Cr( ) T Ar( ) T Gr( )+ +
Val to Val
Phe to Leu
FIG 1 Outline of analyses. (A) Longitudinal blood samples were obtained from 3,190 HIV-infected patients to test for drug resistance mutation as part of their
treatment program. HIV-1 was amplified using PCR and sequenced using population sequencing. The sequences were deposited in either the Stanford Drug
Resistance Database in Palo Alto, CA, or at the EuResist database. (B) The sequences were curated and organized into sequence pairs (n  5,614). (C) The
observed substitutions provided information of the underlying misincorporation rates by considering the set of nucleotide substitutions that were equivalent at
the amino acid level. In these examples, two alternative substitutions could have generated the same synonymous and nonsynonymous substitutions, respec-
tively. Because we assumed that selection acts mostly at the amino acid level, the observed nucleotide substitutions could be considered to be the outcome of a
probabilistic experiment, where the probability of observing any of the equivalent nucleotide substitutions would be proportional to the misincorporation rate.
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G-to-Amutation rates and clearly distinguish the APOBEC3F and
APOBEC3G target sites.
Possible footprintsofAPOBEC3Fand/orotherdeaminase—
but not APOBEC3G—activity on HIV-1 RNA sequences from
chronic infection. To evaluate whether G-to-A mutations in vivo
occurred inmotifs that were known to be favored or disfavored by
APOBEC3F or APOBEC3G, we used the modified version of the
maximum-likelihood-based nucleotide misincorporation rate es-
timator that incorporates the specific trinucleotide target motifs
for APOBEC3F (GAn-to-AAn) and APOBEC3G (GGn-to-AGn)
(see Materials andMethods) (12). This program included correc-
tion factors for mutations that resulted in nonsynonymous (NS)
changes and a factor that modified the rate at which CpG dinucle-
otides were added or removed by a mutation; the latter factor was
necessary because selection against CpGmotifs occurs only at the
nucleic acid level, possibly due to the role of cytosine methylation
in decreasing viral gene expression (22, 33). Therefore, the esti-
matedmisincorporation rates likely reflect the context-dependent
bias in the generation of the mutations (e.g., the motifs that were
favored by APOBEC3F [and possibly other deaminases],
APOBEC3G, orRT/RNAPol II) or unknown selection factors that
were not associated with the amino acid sequences (Tables 1
and 2).
We estimated twomodels for the HIV-1 in vivo relative misin-
corporation rates using the patient-derived sequence pairs: a
GAn-to-AAn model (reflecting APOBEC3F-favored trinucle-
otides) and a GGn-to-AGn model (reflecting APOBEC3G-fa-
vored trinucleotides) (Fig. 2A and B). The results for the param-
eters that were included in both models were similar, and large
variations in the misincorporation rate were observed (Fig. 2A).
The most frequent mutation (G to A) was approximately 25 to 30
times more prevalent than the least frequent mutations (C to G
and G to C). Furthermore, transitions were more frequent than
transversions; the most common transitions were G to A and C to
T, and themost frequent transversionswereC toA andT toA. The
parameters thatmodeled a bias inG-to-Amisincorporation in the
GGn-to-AGn and GAn-to-AAn contexts revealed that the bias
was dependent upon the downstream nucleotide (Fig. 2B).
We next examined the relative preferences of APOBEC3F and
APOBEC3G for trinucleotide motifs, including the favored dinu-
cleotide target of each deaminase (i.e., GAn for APOBEC3F and
GGn for APOBEC3G) (Fig. 2C and D), by reanalyzing the hyper-
mutated sequences from our previous study (12). We previously
demonstrated that APOBEC3G and APOBEC3F display highly
conserved target motif preferences in vitro and in vivo. In agree-
ment with other studies (34, 35), we determined here that
APOBEC3G targeted GGG motifs at least 30 times more fre-
quently than GGCmotifs (Fig. 2C), whereas APOBEC3F targeted
GAAmotifs nearly 15 times more frequently than GAC ones (Fig.
2D). Thus, mutagenesis induced by either deaminase was inhib-
ited when a plus-strand C occurred 2 bp downstream from the
target G (Fig. 2C and D, second columns).
G-to-A mutations were the most frequently observed muta-
tions but did not generally occur in nucleotide contexts favored by
APOBEC3G (Fig. 2C). GG-to-AGmutations in contexts that were
disfavored by APOBEC3G (e.g., GGC-to-AGC) were more fre-
quent than those inAPOBEC3G-favored contexts (Fig. 2B andC).
Because G-to-A mutations were observed less frequently in the
optimal APOBEC3G context GGG (12, 35) than in other contexts
(0.36  1 [95% likelihood interval  0.25 to 0.51]), it is highly
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likely that HIV-1 viruses with mutations in this specific context
were incapable of propagation (i.e., they constituted inactivated,
“dead-end” viruses).
In contrast, GAA-to-AAA mutations did occur 16% more
often than average GA-to-AA mutations and may therefore
have been induced by APOBEC3F or other deaminases
(e.g., APOBEC3A [monocytes/macrophages only], APOBEC3B,
APOBEC3C, APOBEC3DE, and/or APOBEC3H haplotypes II, V,
andVII) (34, 36–42) or a combination of several deaminases, with
contributions from RT and/or RNA Pol II (34, 43–45) (Fig. 2C
and D). The relatively lower likelihood of these mutations occur-
ring in contexts that were disfavored by APOBEC3F and/or pos-
sibly other deaminases suggests that a substantial proportion of
the G-to-A mutations may have been induced by these deami-
nases. Since APOBEC3F, APOBEC3A, APOBEC3B, APOBEC3C,
APOBEC3DE, and APOBEC3Hpreferentially target 5=GAmotifs,
stop codons are less likely to be induced because they would occur
only when amutation occurred in an in-frame “TGGAnn” codon
pair (i.e., “TGG Ann” to “TGA Ann,  where “n” signifies any
base).
Because we analyzed longitudinal sequences from patients and
counted mutations that occurred in APOBEC3F and APOBEC3G
contexts over time, amutation that occurs at one time point and is
carried over to the next time point is likely sublethal. None of the
observed mutations generated stop or start codons, and the ma-
jority of changes were synonymous. Our method is robust to the
selective pressures that operate at the amino acid level because it
focuses only on observed preferences between mutations that are
equivalent on the amino acid level (i.e., mutations that are either
silent substitutions or changed the amino acid to the same amino
acid) (22). Therefore, our results are not confounded by “hitch-
hiking effects” in which, for example, a substitution is fixed by
positive selection of a mutation in a different position in the se-
quence or by sequential evolution at multiple codons. If no mu-
tations occurred in a given dinucleotide context in the longitudi-
nal data set from a patient, then this specific context was not
included in our analyses.
Taken together, our results suggest that APOBEC3G is highly
unlikely to increase HIV-1 diversity in vivo, whereas APOBEC3F
and possibly other deaminases (e.g., APOBEC3A [monocytes/
macrophages only], APOBEC3B, APOBEC3C, APOBEC3DE,
and/or APOBEC3H haplotypes II, V, and VII) may increase
HIV-1 diversification and facilitate viral adaptation and propaga-
tion.
Analyses of HIV-1 env sequences from patients without hy-
permutated viruses during acute and early infection. We ex-
panded our analyses of APOBEC3F- and APOBEC3G-induced
HIV-1 mutagenesis in chronic infection to include sequences
from acute and early infection. Using previously published se-
quences (29), we analyzed 514 HIV-1 RNA envelope sequences
from these disease stages. The previous analysis reported that sev-
eral RNA sequences had greater numbers of G-to-A mutations in
APOBEC3-favored contexts than expected (29); however, these
analyses did not differentiate between APOBEC3F and
APOBEC3G contexts. Our analyses included the dinucleotide
preferences of APOBEC3F and APOBEC3G and demonstrated
that the majority of these G-to-A mutations occurred in
APOBEC3F-favoredmotifs rather than APOBEC3G-favoredmo-
tifs (70% in the APOBEC3F context versus 12% in the
APOBEC3G context for all sequences with G-to-Amutations andT
A
B
LE
2
M
is
in
co
rp
or
at
io
n
ra
te
es
ti
m
at
es
ge
n
er
at
ed
by
an
al
ys
is
of
5,
61
4
pa
ir
s
of
lo
n
gi
tu
di
n
al
n
on
h
yp
er
m
u
ta
te
d
pa
ti
en
t-
de
ri
ve
d
H
IV
-1
po
ls
eq
u
en
ce
s
w
it
h
se
pa
ra
te
m
od
el
pa
ra
m
et
er
s
fo
r
G
A
n
-
to
-A
A
n
a
St
at
is
ti
c
V
al
u
e
fo
r
m
is
in
co
rp
or
at
io
n
ra
te
A
¡
C
A
¡
G
A
¡
T
C
¡
A
C
¡
G
C
¡
T
G
¡
A
G
¡
C
G
¡
T
T
¡
A
T
¡
C
T
¡
G
fA
dd
C
pG
fD
el
C
pG
fG
A
A
to
A
A
A
fG
A
C
to
A
A
C
fG
A
G
to
A
A
G
fG
A
T
to
A
A
T
fD
el
C
pG
.G
A
E
st
im
at
e
0.
43
3
2.
12
5
0.
23
5
1.
49
6
0.
21
5
3.
41
2
4.
83
1
0.
20
5
0.
47
4
0.
64
0
2.
11
0
0.
67
0
0.
27
4
3.
37
2
1.
41
6
0.
73
6
1.
29
7
1.
30
9
6.
05
8
Lo
w
er
95
%
C
I
0.
39
0
1.
98
3
0.
21
2
1.
32
5
0.
17
0
3.
16
1
4.
43
0
0.
16
5
0.
40
3
0.
56
9
1.
96
4
0.
57
3
0.
25
0
2.
91
7
1.
27
4
0.
59
7
1.
08
0
1.
15
4
5.
07
0
U
pp
er
95
%
C
I
0.
48
0
2.
27
6
0.
26
2
1.
69
0
0.
27
3
3.
68
3
5.
26
6
0.
25
5
0.
55
9
0.
72
0
2.
26
7
0.
78
4
0.
30
0
3.
89
6
1.
57
4
0.
90
8
1.
55
7
1.
48
4
7.
22
4
a
Se
e
fo
ot
n
ot
e
a
of
T
ab
le
1.
Armitage et al.
12886 jvi.asm.org Journal of Virology
 o
n
 O
ctober 28, 2014 by KU Leuven University Library
http://jvi.asm.org/
D
ow
nloaded from
 
68% in the APOBEC3F context versus 12% in the APOBEC3G
context for the nonhypermutated sequences only) (Fig. 3), in
agreement with the results of the chronic infection analysis. No
nonhypermutated sequences with GG-to-AG mutations carried
more than a single GG-to-AGmutation, whereas 25% of the non-
hypermutated sequences with GA-to-AA mutations carried mul-
tiple GA-to-AA mutations.
Thus, we determined that G-to-A mutations occurred more
often than expected in APOBEC3F-favored contexts in sequences
from acute, early, and chronic infection, consistent with a role of
APOBEC3F (and possibly other deaminases) in the evolution of
HIV-1 during the course of the disease.
Collectively, our data provide compelling evidence thatG-to-A
mutations accumulate over time in natural HIV-1 infection and
that these mutations are unlikely to be caused by APOBEC3G but
may be induced at least partly by other cytidine deaminases at all
stages of disease.
DISCUSSION
In this study, we investigated the footprint of APOBEC3F and
APOBEC3G activity in HIV-1 evolution in infected patients. We
analyzed thousands of longitudinal, plasma-derived, nonhyper-
mutated pol sequence pairs from more than 3,000 chronically
HIV-1-infected patients (22) to examine whether it is likely that
APOBEC3-induced mutations in vivo are always lethal for HIV-1
or whether they might occur at sublethal levels that increase viral
diversification and aid in adaptation to the host.
As expected, G-to-A transition mutations were the most fre-
quently occurring mutations over time (22, 32); however, our
analyses revealed that their frequency varied greatly depending on
the sequence contexts. Specifically, we observed that G-to-A mu-
tations occurred more frequently in APOBEC3G-disfavored con-
texts than in APOBEC3G-favored contexts, strongly suggesting
that APOBEC3G activity does not contribute to beneficial HIV-1
diversification in vivo. This result is consistent with our previous
in vitro and in silico analyses of APOBEC3G, which indicated that
the activity of even a single APOBEC3G unit is highly likely to be
lethal for HIV-1 (21).
In contrast, we observed a 16% overrepresentation of G-to-A
mutations in APOBEC3F-favored contexts and an underrepre-
sentation of G-to-A mutations in APOBEC3F-disfavored con-
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FIG 2 The examination of APOBEC3G and APOBEC3F mutational footprints within natural HIV-1 sequences. (A and B) A total of 5,164 pairs of partial pol
sequences from 3,190 HIV-1-positive patients were analyzed using the modified maximum-likelihood-based nucleotide misincorporation rate estimation
method. We estimated the nucleotide misincorporation rates in a GGn-to-AGn model and a GAn-to-AAn model across the set of sequence pairs (A), and we
assessed the influence of the two downstreamnucleotides on the observedG-to-Amisincorporation rates (B). TheGGn-to-AGnmodel included parameters that
estimated APOBEC3G-type misincorporation rates, and the GAn-to-AAn model included parameters that estimated APOBEC3F-type misincorporation rates.
In panel A, the relative misincorporation rates are scaled to obtain a geometric mean of “1” for the estimated rates to allow for objective comparisons, whereas
the misincorporation rates are expressed relative to the average G-to-A misincorporation rate in panel B. The relative frequencies of mutation in the trinucle-
otides that contained the known preferred APOBEC3G and APOBEC3F target dinucleotides are shown (APOBEC3G, left “GG”; APOBEC3F, right “GA”), and
the trinucleotides that were most and least favored by APOBEC3G and APOBEC3F in vitro (see parts C and D, respectively) are indicated with arrows. We
previously demonstrated that the preferred APOBEC3G and APOBEC3F tetranucleotide motifs correlated strongly in vitro and in vivo (12). (C and D) We
previously determined APOBEC3G and APOBEC3F tetranucleotide preferences using nearly full-length in vitro-hypermutated HIV-1 genomes (12). These
sequences were reanalyzed in this study to determine the odds ratios (95% confidence intervals in parentheses) by comparing the mutation frequencies between
pairs of trinucleotides that contained the preferred dinucleotide motif targets for APOBEC3G “GGn” (C) and APOBEC3F “GAn” (D). The ratios represent the
relative frequencies of the column over row category. In the set of sequences that were generated in the presence of APOBEC3G (C), GGA-to-AGA mutations
occurred approximately 14 times more frequently than GGC-to-AGC mutations.
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texts, which suggest that APOBEC3F contributes to HIV-1 evolu-
tion. However, these results do not rule out a minor role for other
APOBEC3 proteins, such as, e.g., APOBEC3A (monocytes/mac-
rophages only), APOBEC3B, APOBEC3C, APOBEC3DE, and/or
APOBEC3H haplotypes II, V, and VII (34, 36–42) and/or a con-
tribution from RT and/or RNA Pol II (34, 43–45). The activity of
APOBEC3A differs from that of other deaminases because it ex-
erts its antiviral effect in monocyte/macrophage producer cells
(46) and may be targeted by Vpx (47) but does not restrict HIV-1
replication in the target cell (48). Homogeneous deletion of
APOBEC3B increases the risk of HIV acquisition and AIDS pro-
gression in some cohorts (49) but not all (50), although it is not
normally expressed in lymphoid cells (51). The antiviral effect of
APOBEC3DEhas been demonstrated in a single-cycle experimen-
tal system and in T-cell lines (52, 53) but not in human primary
cells. The impact of APOBEC3H in natural infection is unclear.
However, overexpression of APOBEC3Hhaplotype II restricts the
replication of some lab-adapted HIV-1 strains (37, 54), and hap-
lotypes II, V, and VII are incorporated into virions and restrict
HIV-1 replication in 293T cells (54).
An alternative explanation for the deficit of G-to-A substitu-
tions in APOBEC3G contexts is that most of the other observed
changes were caused by previously occurring unknown positive
selection and that the population adaptation to this selection pres-
sure is complete. This would account for a surprising “lack” of
events in some contexts because the expected “background” neu-
tral rates would be overestimated from a set of changes that were,
in reality, positively selected. However, we suggest that this expla-
nation is unlikely, particularly because most of the observed
changes were synonymous.
A potential limitation of our analyses is the assumption that
alternative equivalent mutations are silent. Although natural se-
lection occurs at the amino acid level and mutations that result in
incorporation of the same amino acid therefore can be considered
silent, some mutations could theoretically facilitate other and/or
further mutations at the next time point. However, if this should
occur, we estimate that the effect would be so weak that it would
have no effect on our overall results.
The results of the chronic HIV-1 infection analysis are strongly
supported by the analyses of the envelope sequences from acute
and early infection (29). G-to-A mutations occurred in
APOBEC3F-favored contexts more often than expected in these
sequences, which suggests that APOBEC3F (and possibly other
deaminases) may play a role in HIV-1 evolution throughout the
course of the disease, e.g., by facilitating immune escape (55).
Because our previous analyses of almost-full-length genomes of in
vitro-mutated HIVIIIB and in vivo patient-derived hypermutated
sequences demonstrated similar patterns and levels of APOBEC3-
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FIG 3 Analysis of mutation characteristics in 514 HIV-1 env sequences from acute and early infection. We divided the sequences from reference 29 into those
with (n 120) andwithout (n 394)G-to-Amutations. First, we askedwhether sequenceswithG-to-Amutationswere hypermutated (1); second, we examined
the hypermutation bias (2) and found that 90% carried GA-to-AA hypermutation; GA is a motif preferentially mutated by APOBEC3F and other deaminases
(e.g., APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3DE, and/or APOBEC3H haplotypes II, V, and VII) but not APOBEC3G. For simplicity, we characterize
this motif as an “APOBEC3F” context in the figure. Third, we examined the Gn-to-Anmutation characteristics in the nonhypermutated sequences with G-to-A
mutations (3) and found that in 68%, mutations were in the GA (“APOBEC3F”) context, whereas 12% were found in the GG (APOBEC3G) context. Two
sequences (1.8%) carried equal numbers of GG-to-AG and GA-to-AA mutations (signified by “”), and 18% carried G-to-A mutations in non-APOBEC3-
preferred contexts. Fourth, we examined whether there were multiple GG-to-AGmutations in the nonhypermutated sequences (4) and found only evidence of
single GG-to-AGmutations. Fifth, we likewise examined if there weremultiple GA-to-AAmutations in the nonhypermutated sequences (5) and found that 75%
of the sequences carried a single GA-to-AA mutation, whereas 25% carried multiple GA-to-AA mutations, in contrast to the GG-to-AG pattern.
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induced mutagenesis (12, 21), the limitation that we are not able
to compare the mutational context in the same gene is unlikely to
affect the results.
Studies of the consequences of APOBEC3G activity for pa-
tient-derived HIV sequences are an area of active research. Previ-
ous studies either support our finding that APOBEC3G is unlikely
to contribute to viral diversification (22, 56, 57) or offer no evi-
dence that contradicts our findings (55, 58). The impact of
APOBEC3G in HIV-1 evolution has also been studied extensively
in vitro using a wide range of assays, lab-adapted HIV-1 strains,
reporter genes, and cell lines, and experiments often include the
nucleoside analogue RT inhibitor 2=,3=-dideoxy-3=-thiacytidine
(3TC or lamivudine) (7, 21, 59–61). The use of 3TC is potentially
problematic because it accumulates to different degrees in differ-
ent cell lines (62–65) and increases intracellular dATP levels (66),
possibly affecting RT misincorporation rates (67). The relevance
of these studies for APOBEC3G’s role in HIV evolution in vivo is
unclear and requires further examination.
The hypothesis that APOBEC3F-inducedmutations in natural
infectionmay occasionally be tolerable during viral propagation is
supported by in vitro studies demonstrating that APOBEC3F has
minimal or no antiviral activity in primary cells or when
APOBEC3F is expressed in cell lines at levels similar to those in
primary cells (68, 69). To some extent, these findings conflict with
the antiviral activity of APOBEC3F observed in other in vitro stud-
ies, although the observed antiviral effect was consistently less
than that due to APOBEC3G (4), and Vif-deficient lab-adapted
HIV-1 produced in an APOBEC3F-null/APOBEC3G cell line did
not exhibit a significant change in the fraction of hypermutations
that occurred within 5=GG or 5=GA dinucleotides (41). However,
the latter study did not consider any contribution from RT and
reported that mutations in the 5=GA context were nearly absent
only in HIV-1 produced in APOBEC3F-null/APOBEC3DE
knockdown cells; this finding contrasts with other reports that
APOBEC3DE has no or little antiviral activity (34, 57, 70).
The conflicting results of in vitro studies highlight the need
to examine patient-derived HIV-1 sequences for footprints of
APOBEC3 activity to understand the consequences of this activity
forHIV-1 evolution in natural infection. The results of the present
study are largely in agreementwith those of a cross-sectional study
of approximately 2,000 full-lengthHIV-1 sequences from theHIV
database that found no evidence of an evolutionary footprint of
APOBEC3G (56). However, in contrast to the results presented
here, the previous study identified only a nonsignificant trend
that suggested footprints of APOBEC3F activity. The latter result
could be due to the higher noise levels of the previous study, which
may have been the result of the cross-sectional nature of the study
and the use of HIV B sequences from patients in different disease
stages. Analyzing longitudinal sequences allowed us to distinguish
between founder effects and mutations that develop within a pa-
tient and potentially facilitated the identification of nonlethal,
APOBEC3-induced mutations, which are likely to accumulate
over time, by comparing within-patient sequences from different
time points.
Both overlapping and distinct Vif domains are involved in the
binding of APOBEC3F and APOBEC3G and other deaminases,
such as, e.g., APOBEC3C and APOBEC3DE (10, 40, 56, 71–76);
however, it is likely that a single Vif molecule binds to only one
APOBEC3 molecule. Because the number of Vif molecules in
HIV-infected cells at any given time point is finite, we hypothesize
that viral selection may favor the preferential binding of Vif to
APOBEC3G because it would confer a greater survival advantage
toHIV-1 than binding to other deaminases.We acknowledge that
APOBEC3F and other deaminases can restrict HIV-1 prolifera-
tion in vitro (53, 77–79) and possibly in vivo, and thus we hypoth-
esize only that the lethal antiviral effects of these deaminases are
less than that of APOBEC3G.
The greater viral survival advantage of APOBEC3G-Vif neu-
tralization is suggested by the following: (i) APOBEC3G is more
likely to generate stop codons than APOBEC3F and other deami-
nases (3, 12), (ii) the processive single-stranded DNA scanning
behavior of APOBEC3G (“jumping” and “sliding”) increases its
mutagenic potential relative to that of APOBEC3F (predomi-
nately “jumping”) (80), (iii) most (81–86) although not all (87)
studies demonstrate that APOBEC3G expression levels correlate
inversely with viral load and disease progression in adults, (iv)
APOBEC3G expression levels are higher in long-term nonpro-
gressors than in uninfected controls and lowest in rapid progres-
sors (81), (v) APOBEC3GmRNA is expressed at higher levels than
that of APOBEC3F in lymphocytes and lymphoid tissue (88, 89),
and APOBEC3F is not expressed in monocytes/macrophages and
dendritic cells, whereas APOBEC3G is (71), (vi) APOBEC3F and
other deaminases have little or no antiviral effect in primary cells
or when expressed at similar levels in cell lines (68, 69), although a
cumulative antiviral effect of APOBEC3F, albeit less than that of
APOBEC3G, was observed in a long-term (27 days) culture of
lab-adapted virus in CD4 T cells and monocyte/macrophages
(4), (vii) APOBEC3F has no significant effect on virus infectivity
when stably expressed in HeLa cells, even though it was packaged
into nascent virions (68), (viii) the protein expression levels of
APOBEC3G are higher than those of APOBEC3F in peripheral
blood mononuclear cells (PBMCs) from different donors, al-
though the use of different antibodies precluded an accurate
quantification of protein expression (69), and (viiii) APOBEC3G
had a stronger antiviral effect than APOBEC3F when they were
expressed as fusions with the FLAG-epitope at the same levels in
cell lines (90). We acknowledge that there may be a discordance
betweenmRNA and protein expression levels and antiviral effects
and that these studies do not analyze the degree to which each
APOBEC3 inhibits reverse transcription, stimulates cDNA degra-
dation, or inhibits integration; however, these limitations do not
challenge the conclusion that APOBEC3G activity is more delete-
rious to HIV survival than the activities of other deaminases (4).
Based on the results of the analyses performed in this study, we
hypothesize that Vif selection for preferential binding to
APOBEC3G results in the efficient elimination of APOBEC3G
from assembling virions while allowing some incorporation of
APOBEC3F (and/or other deaminases) into virions. In addition, it
is possible that selection pressures may favor both the preferential
binding of APOBEC3G and the less efficient binding of
APOBEC3F and possibly other deaminases. This hypothesis is
supported by reports that APOBEC3G and APOBEC3F rarely co-
mutate the same HIV-1 genome (91) and by a study of plasma-
derived HIV-1 RNA env sequences in which 10/3,449 sequences
were hypermutated and 9/10 predominantly carried APOBEC3F-
type GA-to-AA mutations (57).
However, other factors beyond viral selection pressures may
affect the interaction of Vif with APOBEC3. The pleiotropic ef-
fects of mutations caused by other selective pressures could affect
Vif binding to APOBEC proteins and/or Elongin C, such as the
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Wild-type Vif excludes 100% of hA3G
but may be targeted by CTL
  
CTL escape mutation in Vif results in 80% hA3G exclusion, immune evasion
and inactivation of 20% of new infections  
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FIG 4 Model of proposed pleiotropic fitness effects of a CTL escapemutation. In thismodel, wild-type Vif can exclude all APOBEC3F andAPOBEC3Gunits but
encodes a CTL epitope that can be recognized by the host’s CTL response. A CTL escape mutation within this epitope results in a hypothetical 20% decrease in
the ability of the mutated Vif to bind to APOBEC3F and APOBEC3G. (A) Incorporation of APOBEC3G. We assumed that incorporation of APOBEC3G into
HIV-1 resulted in viral inactivation in 100% of cases (based on the findings in reference 21). Thus, the incorporation of APOBEC3G in 20% of nascent virions
results in inactivation of 20% of the viral population. (B) Incorporation of APOBEC3F. Based on the results of the analysis of sequences from chronic infection
(Fig. 3), we estimated that about 10% of the sequences with APOBEC3F-induced G-to-A mutations would be hypermutated. Thus, if APOBEC3F were
incorporated into 20% of nascent viruses, only 10% of these would be hypermutated, resulting in inactivation of 2% of the viral population, whereas 18%would
carry nonlethal APOBEC3F-induced mutations that might facilitate viral adaptation to the host.
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selective pressure of Vif-specific cytotoxic T cell (CTL) responses.
CTLs recognize fragments of viral proteins (CD8 epitopes) that
are presented by HLA on the infected cell surface and subse-
quently kill the infected cell. Numerous studies have observed that
CTLs frequently target CD8 epitopes in Vif (92–98). The pleiotro-
pic effects of CTL-induced escape mutations that prevent viral
recognition and the killing of infected cells depend on the affected
Vif region and may destabilize the interactions between Vif and
APOBEC3F, APOBEC3G, and/or other deaminases or the inter-
actions between Vif and Elongin C. The importance of the specific
Vif sequence in determining the biological outcome of the inter-
action between Vif and a range of APOBEC3 proteins is empha-
sized by reports demonstrating that, e.g., APOBEC3C and
APOBEC3B are neutralized by some Vif variants but not others
(40) and that Vif subtype variability affects the efficiency of the
interaction with APOBEC3G (99).
We hypothesize that suboptimal Vif-APOBEC3G interactions
are the result of a trade-off by the virus between competing fitness
costs. For HIV-1, the disadvantage of producing defective viral
progeny as a result of hypermutation is outweighed by the possible
advantages of either nonlethal APOBEC3F-induced mutagenesis
(and/or nonlethal mutagenesis by other deaminases) or CTL es-
cape to viral progeny that avoid hypermutation (illustrated in Fig.
4). Because defective viruses generated by APOBEC3G have been
demonstrated to potently activate HIV-specific CTL responses
(100), hypermutation may increase the magnitude of CTL re-
sponses and the killing of infected cells, which would subject the
HIV-1 population to greater fitness costs and increase the selective
pressure to escape these CTL responses. However, Vif-specific
CTL responses may be harmful to the host when they result in
mutations that increase nonlethal APOBEC3F-inducedmutagen-
esis (or nonlethal mutagenesis by other deaminases) and thereby
facilitate viral adaptation. This could potentially lead to an in-
crease in the HIV load in plasma, as suggested by a report of
significantly higher viremia in patients with Vif-specific CTL re-
sponses (95).
In conclusion, we demonstrated that APOBEC3G activity is
unlikely to increase HIV-1 evolution in vivo, whereas the activ-
ity of other members of the APOBEC3 family, specifically
APOBEC3F, may increase HIV-1 diversification through sub-
lethal mutagenesis and thereby facilitate viral adaptation to the
host. Therefore, vaccine-induced Vif-specific CTL responses
and drugs that manipulate the interplay between Vif and
APOBEC3 should be tested with caution because theymay have
either beneficial or detrimental clinical effects on the patient
depending on how they affect the binding of Vif to various
members of the APOBEC3 family.
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